Biomarcador Geral Mama

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?

Escrito por Carla Brito Lopes
Circulating tumor cell (CTC) count has prognostic significance in metastatic breast cancer, but the predictive utility of CTCs is uncertain. Molecular studies on CTCs have often been limited by a low number of CTCs isolated from a high background of leukocytes.
Improved enrichment techniques are now allowing molecular characterisation of single CTCs, whereby molecular markers on single CTCs may provide a real-time assessment of tumor biomarker status from a blood test or “liquid biopsy”, potentially negating the need for a more invasive tissue biopsy.
The predictive ability of CTC biomarker analysis has predominantly been assessed in relation to HER2, with variable and inconclusive results. Limited data exist for other biomarkers, such as the estrogen receptor.


In addition to the need to define and validate the most accurate and reproducible method for CTC molecular analysis, the clinical relevance of biomarkers, including gain of HER2 on CTC after HER2 negative primary breast cancer, remains uncertain. This review summarises the currently available data relating to biomarker evaluation on CTCs and its role in directing management in metastatic breast cancer, discusses limitations, and outlines measures that may enable future development of this approach.
Pode descarregar o artigo completo aqui:10.3390/cancers6020684

Citation: [Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?
Turner, Natalie; Pestrin, Marta; Galardi, Francesca; De Luca, Francesca; Malorni, Luca et al. (2014)
Cancers vol. 6 (2) p. 684-707]. Reprinted with permission under the terms of the Creative Commons Attribution License.

Sobre o autor

Carla Brito Lopes

Carla nasceu em Viana do Castelo em 1977. Licenciada em Anatomia Patológica, Citológica e Tanatológica pela Escola Superior de Tecnologia da Saúde em Lisboa. Concluiu a certificação em Laboratory Management pela ASCP (American Association of Clinical Pathology) em Setembro de 2016. Mestre em Genética Molecular e Biomedicina pela Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa. Trabalhou no Centro Hospitalar Lisboa Central entre 1998 e 2015, exercendo histopatologia e imunohistoquímica, sendo co-responsável pelo sector. Trabalha no Dr. Joaquim Chaves, Laboratório de Anatomia Patológica desde 2004 onde exerce funções de Coordenação Técnica e da Qualidade.